• More than a dozen cannabis reform bills were passed by the California legislature during the summer
• Governor Newsom signed 10 of the bills
• SGMD is focused on strengthening its presence in a variety of spaces, including cannabis

As the California legislature ended its session last month, more than a dozen cannabis reform bills were approved and sent to Governor Gavin Newsom for his consideration (https://ibn.fm/TLbMU); ultimately, the governor signed 10 of them (https://ibn.fm/HOL7u). The show of government support for cannabis in the state bodes well for California cannabis companies, including Sugarmade (OTC: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, including cannabis. “For too many Californians, the promise of cannabis legalization remains out of reach,” said Governor Newsom. “These measures build on the important strides our state has made toward this goal, but much work remains to build an equitable, safe and sustainable legal cannabis industry. I look forward to partnering with the legislature and policymakers to fully realize cannabis legalization in communities across California.” A Marijuana Moment article reported that “in the past several weeks, more than a dozen cannabis reform bills crossed the finish line in Sacramento, pending action from Gov. Gavin Newsom.” Included in those bills was one that would prohibit localities from banning medical cannabis deliveries in their areas, “a move that advocates say will both improve patient access and help fill voids throughout the state where no cannabis license types have been authorized,” the article stated. Other bills included a measure providing employment protections for employees who use marijuana during their off hours, a bill designed to streamline record sealing for people with eligible marijuana-related convictions, and legislation that would set the state up to allow interstate cannabis commerce. The full list of bills signed by the governor include the following: AB 1706, cannabis crimes: resentencing; AB 1646, cannabis packaging: beverages; AB 1885 by cannabis and cannabis products: animals: veterinary medicine; AB 1894, integrated cannabis vaporizer: packaging, labeling, advertisement, and marketing; AB 2210, cannabis: state temporary event licenses, venues licensed by the Department of Alcoholic Beverage Control, unsold inventory; AB 2188, discrimination in employment: use of cannabis; AB 2568, cannabis: insurance providers; AB 2925, California Cannabis Tax Fund: spending reports; SB 1186, Medicinal Cannabis Patients’ Right of Access Act; and SB 1326, cannabis: interstate agreements. According to the governor’s office, these bills “build on the administration’s efforts to strengthen California’s cannabis legalization framework. As part of this year’s state budget, the governor signed legislation to provide tax relief to consumers and the cannabis industry; support equity businesses; strengthen enforcement tools against illegal cannabis operators; bolster worker protections; expand access to legal retail; and protect youth, environmental and public safety programs funded by cannabis tax revenue. “To expedite policy reforms that prioritize and protect California consumers’ health and safety, the governor has directed the California Department of Public Health to convene subject matter experts to survey current scientific research and policy mechanisms to address the growing emergence of high-potency cannabis and hemp products,” the governor’s announcement continued. “The governor has also directed the Department of Cannabis Control to further the scientific understanding of potency and its related health impacts by prioritizing the funding of research related to cannabis potency through its existing public university grants.” Sugarmade is focused on strengthening its presence in a variety of spaces, including cannabis. The company is rethinking metrics to leverages its portfolio data to “quickly and intuitively understand what we need to focus on creating today to satisfy customers tomorrow, improving efficiency, profit margins, and top-line sales,” (https://ibn.fm/d6pmP). SGMD’s brand portfolio currently includes CarryOutsupplies.com, SugarRush(TM), NUG Avenue, J Grade Farm, Lemon Glow and Budcars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002
• This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported
• The company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the drug was safe and well tolerated. Results from this study were well received by the SRC, who also expressed their optimism for Odyssey’s completion of the MAD portion of its Phase I trial and subsequent Phase II and III studies
• Odyssey looks to offer a viable solution for treating concussions, regarded as a significant “unmet” medical need. It also looks to capitalize on a growing market projected to be valued at $8.9 billion by 2027

Odyssey Health (OTC: ODYY), an enterprise committed to developing unique, life-enhancing medical products, marked a successful close of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial (https://ibn.fm/pnUwS). While making the announcement, Odyssey’s Chief Executive Officer (“CEO”), Michael Redmond, expressed how pleased he was with the safety profile of the company’s concussion pharmaceutical treatment, PRV-002. “As we come close to completing the Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment, PRV-002,” he noted. “I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting,” he added. Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and in Cohort II, patients received a high dose of the drug. The second Cohort reflected the success of the first, where the drug was well tolerated and proved safe with no severe adverse events reported. On July 12, 2022, Odyssey announced the successful completion of its Phase I Single Ascending Dosing (“SAD”) clinical trial, which also involved administering PRV-002. This study proved that the drug was safe and well tolerated and would lay the foundation for the currently-ongoing MAD clinical study (https://ibn.fm/vSh7h). At the time, Dallas Hack, the Managing Director (“MD”) and member of the Safety Review Committee (“SRC”), reckoned: “After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (‘MAD’) portion of the Phase I clinical trial where subjects are treated once daily for five straight days.” Philip Ryan, the MD and Principle Investor for Nucleus Network, noted: “PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002.” “We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients,” he added. Odyssey, so far, has lived up to its expectations and those of the SRC, proving the overall safety of its novel drug. With concussions representing a significant “unmet” medical need affecting millions worldwide, the company is inching closer to offering a viable solution that will benefit patients. In addition, it is positioning itself to take advantage of an industry projected to be valued at $8.9 billion by 2027, up from $6.9 billion in 2020 (https://ibn.fm/LNyM3). Odyssey is currently in the process of selecting clinical sites and developing the Investigator’s Brochure for the Phase II trial. As of July 2022, the company was still in discussions with military training sites for Phase II and III clinical trials, which it hopes to kick off later this year. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• EverGen Infrastructure Corp. announces upgrade from OTCQB(R) Venture Market to OTCQX market in US; Company’s common shares to be quoted under “EVGIF” symbol
• OTCQX listing provides EverGen increased visibility and access to broader investor audience as company gears up to continue to execute on its ambitious growth plans
• This move comes amid favorable market conditions; global waste-to-energy market is projected to grow at a CAGR of 15.62% and reach USD 103.95 billion by 2027

As renewable natural gas (“RNG”) rapidly transforms from niche fuel to mainstream replacement for conventional natural gas, opportunities open up in the sector and EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) appears poised to seize them. After what could be described as a hot streak in which the company embarked on a nationwide expansion, this leading Canadian renewable energy company and renewable natural gas infrastructure platform is gearing up for the next chapter in its growth journey. The company has announced that its common shares were to commence trading on the OTCQX(R) Best Market in the United States under the symbol “EVGIF” (https://ibn.fm/5piOX). For EverGen, this milestone marks an upgrade from the OTCQB(R) Venture Market, where the company’s common shares had been trading since February 2022 (https://ibn.fm/udiEh). After a seven-month stint on this platform reserved for early-stage and developing US and international companies that cannot yet qualify for the most rigorous entry requirements, EverGen progressed toward the top tier OTC market – OTCQX(R) Best Market (OTCQX). The company’s financial disclosure and Real-Time Level 2 quotes are available for US investors at www.OTCMarkets.com. The OTCQX listing helps public companies enhance their liquidity, increase visibility, and expand investor reach, allowing them to diversify their shareholder base through an established, SEC-recognized public market. For example, investors who don’t have access to trading on the TSX Venture Exchange will be able to access EverGen’s common shares through regulated US broker-dealers. “During this milestone rich quarter for EverGen, we are pleased to provide increased access and liquidity for investors in the US who seek to participate in the energy transition,” announced Chase Edgelow, CEO of EverGen. “An upgrade to the OTCQX in the United States is a natural progression for EverGen allowing us to introduce our RNG infrastructure platform to a broader audience as we continue to execute on our growth plans with clear visibility to deliver over 1 million gigajoules of RNG annually,” he concluded. This move comes amid a burgeoning alternative energy market and a strong push for energy transition toward greener solutions, including those based on using waste to create fuel. RNG sector uses organic waste such as food, agriculture, wood, and wastewater that would otherwise release methane, the most potent greenhouse culprit, to produce RNG. As a green energy source interchangeable with conventional natural gas, RNG has the potential to slash carbon emissions in a cost-effective way. Unlike its conventional counterpart, RNG is not a fossil fuel but a clean and affordable waste-derived fuel that can offer a much-needed response to the pressing needs to decarbonize the economy. Landfills are among the biggest sources of methane, a major contributor to global warming, so tackling waste seems pivotal in progressing toward a greener society (https://ibn.fm/80LCs). According to the California Air Resources Board, RNG sourced from landfill-diverted waste can reduce greenhouse gas emissions by 125% (https://ibn.fm/KOoHC). As the international race toward a more climate-friendly economy accelerates, Canada aims to position itself as a global leader in investment in renewable energy. Although many RNG projects are emerging across the country, this may be just the beginning of what is possible in terms of the potential to slash greenhouse emissions. Recent research shows that the global waste to energy market is projected to reach USD 103.95 billion by 2027, growing at a CAGR of 15.62% from USD 50.31 billion in 2022 (https://ibn.fm/U7o1U). In a country that leads when it comes to RNG use, EverGen seems to have emerged as a high-growth pioneer that rapidly expands its footprint across three provinces – from British Columbia, where it had its beginnings, to new projects in Alberta and Ontario. The company remains committed to building reliable infrastructure that aims to turn low-value organic waste into a valuable renewable energy resource and establish itself as an emerging leader in an industry that is yet to flourish. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• 40% of large enterprises are already experimenting with quantum computing to solve some of their most complex problems, according to 451 Research
• Optimization problems make up a significant portion of the enterprise problem universe, and annealing quantum computers are uniquely effective at solving these types of problems
• D-Wave is the only provider building both annealing and gate-model quantum computers that provide opportunities for businesses looking to optimize at scale

The classical computer architecture relies on binary coding, which assigns values of 0 or 1, limiting the decision-making process to a return result of one. The binary space cannot handle large volumes of data with many variables and requires those loading the data to compress, reduce, or limit the data being processed, resulting in lower quality solutions. Businesses representing a variety of industries, like manufacturing, logistics, financial services, and life sciences, rely on optimization to help them tackle common obstacles and problems in the computing world – which binary coding cannot support at scale. The quantum computing framework is multi-dimensional. Using qubits, quantum computers can represent superposition states between 0 and 1, allowing them to represent an exponentially larger state of space to process and store data. With the limitations of classical computers becoming more apparent, quantum computing is now helping businesses optimize data and bring problem-solving to scale. D-Wave Quantum (NYSE: QBTS) is a leader in quantum computing systems, software, and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, and financial modeling. As a pioneer in its industry, D-Wave is the first company building both annealing and gate-model quantum computers. D-Wave’s customer success stories provide firsthand experiences of how its quantum applications benefit industries, solving problems from grocery optimization to protein design – with use cases that illustrate the value quantum has brought to the enterprise (https://ibn.fm/H6bUn). Spain’s leading financial group CaixaBank worked with D-Wave to implement two financial quantum hybrid computing applications designed to optimize the investment portfolio and improve investment hedging calculation. Leveraging D-Wave’s Leap(TM) quantum cloud service and quantum hybrid solvers brought multiple business benefits to CaixaBank, including an up to 90% decrease in time-to-solution for investment portfolio hedging and portfolio optimization (https://ibn.fm/71eVQ). “We have always been an innovation-first organization, and very early on we recognized that investing in quantum computing could help us more efficiently provide state-of-the art products and services in order to offer the best client experience,” said CaixaBank CEO Gonzalo Gortazar. D-Wave’s quantum system was also successfully leveraged by SavantX to tackle supply chain problems at the Port of Los Angeles, the United States’ busiest port with the equivalent of over 10 million 20-foot containers transiting the port in 2021 alone. SavantX utilized D-Wave’s quantum technology to develop the Hyper-Optimized Nodal Efficiency Engine (“HONE”) framework, with the purpose of streamlining operations at Pier 300, one of the port’s largest terminals. HONE helped optimize the pier’s operations significantly, leading to a 50% increase in daily deliveries per crane, lower waiting times for cargo trucks picking up payloads and an overall more effective crane utilization (https://ibn.fm/IV7D3). “Not all problems are optimization problems, but for the ones that are, there’s a huge opportunity to bring value into the equation,” said SavantX CEO Ed Heinbockel. “We’ve tasted the power of quantum, and we’re very, very excited about it.” D-Wave Launch(TM) is the company’s onboarding platform, designed to help businesses easily start their quantum computing journey. The company is currently working to enable enterprises, governments, developers, and researchers to access the power of quantum computing, today (https://ibn.fm/87rX7). For more information, visit the company’s website at www.DWaveSys.com. NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmia
• HeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhere
• BEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability

News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States (https://ibn.fm/FN4BR), and recent reports suggest that COVID-19 may cause heart problems (https://ibn.fm/7QAky) and that the incidence of heart attacks in people under age 40 is increasing (https://ibn.fm/lFzjh). Many companies are working to provide support for this growing problem, including HeartBeam (NASDAQ: BEAT), a cardiac technology company that just received a patent for a proprietary device (https://ibn.fm/RA8EP). According to a recent announcement from the company, the United States Patent and Trademark Office issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology. HeartBeam, a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart-attack detection anytime, anywhere, noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting. “This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability.” Currently, the ECG patch monitor market is limited to detecting arrhythmias using single-lead ECG devices. HeartBeam’s technology uses a synthesized 12-lead ECG that can aid physicians in both arrhythmia detection and ACS diagnosis, including myocardial infarction (heart attack) and angina. According to the company, the new patent follows HeartBeam’s already-granted core patents for remote detection of heart attacks. “The issued patch patents significantly increase HeartBeam’s intellectual property footprint,” the company stated. “And they further widen the impact HeartBeam’s technology could have on cardiac patients and their physicians.” The announcement noted that ECG monitors available today are primarily used for detection of abnormal heart rhythms associated with atrial fibrillation or syncope. According to Martin Burke, DO, FACC, a cardiac electrophysiologist and chief scientific officer of the CorVita Science Foundation, “a 12-lead ECG patch would provide additional information to aid in diagnosing conditions such as ACS or more specific arrhythmias that current single-lead patches cannot accurately detect.” HeartBeam’s exclusive platform applies a suite of proprietary algorithms to simplify vector electrocardiography. The platform can quickly and easily identify whether symptoms may stem from a heart attack, potentially enabling care to be accurately identified and expedited. The company currently has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the only credit-card-sized, 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system designed to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Lexaria is the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology
• DehydraTECH is designed to enhance the performance of fat-soluble active pharmaceutical ingredients (“APIs”), molecules, and drugs by increasing their bioavailability
• Through animal and human studies, Lexaria has shown that DehydraTECH increases the bioavailability of antiviral drugs, CBD, oral nicotine and more
• The company is focusing on multiple mainstream applications of its technology that rerrcould address serious unmet patient needs
• Lexaria is currently keen on developing a potential treatment for hypertension

Last summer, drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) announced a review of its successful 2021 antiviral drug program. The program, which aimed to determine whether the processing of leading antiviral drugs using its patented DehydraTECH could exhibit evidence of superior oral absorption relative to controls; whether DehydraTECH processing of these compounds would preserve the expected viral inhibitory performance; and whether DehydraTECH does not alter or degrade the drug molecules chemically, met all three of these objectives (https://ibn.fm/vgfO7). Lexaria specifically probed the bioavailability of five DehydraTECH-processed antiviral drugs for SARS-CoV-2, HIV/AIDS, and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake. Lexaria’s vision for DehydraTECH is not limited to antiviral drugs as the company is also focusing on other possible mainstream applications of its disruptive drug delivery platform, including but not limited to oral nicotine and cannabidiol (“CBD”). Pharmacokinetic studies evaluating these compounds have, in fact, shown that DehydraTECH delivers higher quantities of these APIs in less time. For instance, compared to controls, DehydraTECH-CBD delivered 317% more CBD to the blood a half hour after ingestion, according to a 2018 human study (https://ibn.fm/CXYRe), while DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls as seen in an animal study (https://ibn.fm/i6YYL). DehydraTECH’s ability to increase the performance of different APIs represents multiple commercial opportunities that, when tapped, could potentially address serious unmet patient needs. Of the various markets the company is evaluating, hypertension is a good case in point. Currently, only 1 in 5 adults with hypertension have it under control (https://ibn.fm/F3wgK), a worrying statistic attributable to the troublesome side effects of medication, which cause the patients to abandon their prescriptions (https://ibn.fm/Yukig). Unfortunately, this means the overwhelming majority are at an increased risk of developing maladies such as heart, brain, and kidney disease or even death – hypertension is a major cause of premature death worldwide. But Lexaria is positioning DehydraTECH-CBD as a potential solution. Through four human studies, the company has shown that DehydraTECH-CBD is well tolerated by all subjects, with no serious adverse events or side effects reported or observed. Moreover, the first three of these studies represented significant milestones in the pursuit of potential hypertension treatment. They have evidenced a rapid and sustained drop in blood pressure, a 23% average reduction in overnight blood pressure and reduced arterial stiffness, and attenuated pulmonary artery systolic pressure by approximately 5 mmHg, respectively (https://ibn.fm/yd6GR). Lexaria expects to announce the results of its fourth human study, HYPER-H21-4, whose dosing was completed this summer, in due course (https://ibn.fm/O8OJr). HYPER-H21-4 is designed to enhance the company’s understanding of DehydraTECH-CBD for the treatment of heart disease and other disease states related to increased arterial stiffness. In addition, it is intended to improve Lexaria’s likelihood of success toward an Investigational New Drug (“IND”) application filing seeking the FDA’s approval to begin registered Phase 1b clinical testing. Having held a successful Pre-IND meeting, Lexaria is currently preparing to file the IND application by late 2022 or early 2023 (https://ibn.fm/eXQq1). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Data Bridge Market Research forecasts a 13.7% CAGR for the casino online gambling market to reach $144.74 billion in 2028
• Golden Matrix Group is demonstrating growth in both its B2B and B2C businesses, as it prepares to enter the Mexican markets
• GMGI revenue for the first nine months of fiscal 2022 was $26.46 million, up 237% from a year earlier, while the company notched its 16^th consecutive profitable quarter

For decades, there was little substantial innovation in the gambling industry and then along came the miracle of the internet and changed everything with the emergence on online gaming. Still, most traditional casino operators were slow to embrace the digital opportunity until the COVID-19 pandemic and subsequent lockdowns limited travel and shuttered their doors. That sparked a renaissance and provided a growth opportunity for companies like Golden Matrix Group (NASDAQ: GMGI), a provider of turnkey and white label gaming platforms, Esports technology and gaming content. Even with casinos opened again, the trend towards digital gaming is accelerating with no indications it will slow. Data Bridge Market Research this month forecast 13.7% compound annual growth for the casino online gambling market to reach $144.74 billion in 2028. Drivers abound, including increasingly realistic graphics where the lines between video games and online gaming are becoming blurred. Toss in the emergence of virtual and augmented reality to create the sensation of being in a casino and suddenly people have more money for gambling by saving on travel costs in favor of putting on a headset. Golden Matrix’s GM-AG System is the industry standard for gaming platforms, including leading graphics and over 10,000 games to give casino operators a copious number of options and management software to keep customers happy and loyal to their brand. As a rule, casinos can’t have enough online table games, which is right in GMGI’s wheelhouse. According to Gaming.com, cons of Caesars online casino, the company with the highest payout rate in the U.S., include a need for more online games. Golden Matrix is only scratching the surface of the bounds of its potential domain. Most of its business has historically been business-to-business with operators focused in Asia-Pacific. Last year, the company bought 80 percent of RKings Competitions Ltd., marking its entrance in the European markets, as well as business-to-consumer segment. The company is amid its next expansion move, which will bring RKings’ competitions to the Mexican markets. Through July, RKings has over 229,000 registered users. The growth is translating directly to quarterly results. In fact, the efficiently run company holds a streak of 16 consecutive profitable quarters. It is also flush with cash, having $15.87 million in cash and cash equivalents heading into its August-October quarter. During its third fiscal quarter ended July 31, 2022, Golden Matrix reported revenue of $9.1 million, up 180% from $3.25 million in the year prior quarter. Sales were nearly even between B2B and B2C segments at $4.26 million and $4.85 million, respectively. Net income for the quarter was $628,332, topping $484,613 in profits in Q3 fiscal 2021. For the first 9 months of the fiscal year, the company logged revenue of $26.46 million, up 237% from $7.84 million a year earlier. Net income was $1.56 million compared to $664,757 last year. “Because of the highly competitive nature of our industry, we are continually upgrading our systems and gaming content offerings to support the needs of our millions of participants,” said Golden Matrix CEO Anthony Brian Goodman in a news release on the recent quarter. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• California’s Consumer Privacy Act, Privacy Rights Act, and Europe’s General Data Protection Regulation represent a changing data market
• Reklaim is a leader in compliant data with a comprehensive platform that allows consumers to re-take control of their data and be compensated should they decide, it can be bought and sold
• Reklaim’s revenue jumped 277% year-over-year to $645,008 in Q2 as the company grows organically and explores accretive M&A opportunities

In years gone by, not long ago, companies were quietly hoarding as much data as possible from consumers, then promptly selling it for the maximum amount with little to no concern if the consumer liked it or not. Thankfully, a paradigm shift is happening with new privacy laws in North America, namely the California Consumer Privacy Act (“CCPA”) and the California Privacy Rights Act (“CPRA”), and Europe with its General Data Protection Regulation (“GDPR”), paving the way for litigation against data companies if they don’t comply. That has created an opportunity for companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) to burst on the scene with an innovative privacy-compliant identity ecosystem. Unable to secretly swipe consumer data, many companies in the data space find themselves in unfamiliar territory with little infrastructure to communicate with consumers. There is no skirting the laws, which undergirds why Reklaim believes many of these firms coping with the changing regulatory climate “will suffer significant revenue declines, and those without a compliance partner will likely cease to exist.” The implications are tremendous. Consider that Facebook parent Meta said it expects a $10 billion write-down on revenue in 2022 because of changes Apple made to halt user tracking on external applications. To be clear, Apple’s App Tracking Transparency feature doesn’t stop all data collection, but it did upend the $200 billion US data market and caused data users to scramble to rethink strategies, just like they have to do with the shifting regulatory landscape. For enterprise software juggernaut Oracle, a massive class-action lawsuit has been filed alleging privacy violations for collecting, profiling, and selling data on five billion users worldwide. Further evidence of the trend is shown in the Federal Trade Commission filing a lawsuit against data broker Kochava Inc. for selling geolocation data from mobile devices that identified people at places of worship, addiction clinics, domestic violence shelters, and other highly sensitive locations. Reklaim is an eye-opener, allowing consumers to log in to their platform and confirm their identity, unlocking data collected on them, bought, and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms, and data companies. The company also has a subscription service for consumers that shrinks the amount of data leaking from their devices and delivers alerts on password and third-party data breaches. As described by Sophic Capital, the supply of data is dramatically shrinking owing to new laws and actions of Apple and Google, which are planning on banning third-party cookies in Chrome, which will remove 65% of tracking from 1.8 billion websites on the open web today; further complicating companies trying to monetize data. Compliant data is not going to be the gold standard; it will be the only standard for brands to walk confidently within the parameters of the law. Reklaim also provides the ability to scale compliant targeting marketing initiatives with its database of compliant data for 350+ million profiles in the U.S. alone. With the CCPA and CPRA going into effect shortly, business is picking up at Reklaim. During the second quarter, total revenue increased 277% to $645,008 from Q2 0221 and 65% from the first quarter of 2022. Recurring revenue accounted for 85% of the total revenue in Q2 2022 and was up 87% during the year’s first half compared to a year earlier. According to Reklaim CEO Neil Sweeney, the company is focused on driving costs out of operations and exploring strategic acquisitions that can be immediately accretive to bolster the top and bottom line at a time when the compliant data market is about to go through a growth spurt. Realizing a “strike when the iron is hot” opportunity, Reklaim intends to increase its sales force to meet demand and foster further organic growth. The addressable market in the U.S. is transformational on its own. However, this is global. Market research firm Gartner forecast in May called for a regulatory evolution that will result in 75% of the worldwide population having its personal data covered under privacy regulations by the end of 2024. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Flora Growth is a global cannabis cultivator, product builder, and supplier, experiencing continued growth thanks to strategic acquisitions and an expanding supply chain for marketing its brands in various countries
• Flora announced its most recent acquisition in September — a deal to acquire the assets of the No Cap Hemp Co. brand in exchange for payment of 10 percent of the No Cap brand revenues up to a maximum of $2 million
• The deal grants Flora an immediate revenue stream free of closing cost considerations
• Flora has seen revenues skyrocket over the past year, with a 604 percent YOY increase in the H1 reporting period

Global cannabis cultivator, product manufacturer and distributor Flora Growth (NASDAQ: FLGC) is measuring its success in rapidly rising revenues brought on by strategic acquisitions and the expanding international movement of its brands. The company recently reported a 604 percent increase YOY in its H1 revenues to about $15 million, which was also a 117 percent increase over the previous half-year financial report, and is anticipating new momentum from the recent acquisition of the No Cap Hemp Co. brand by Flora’s wholly owned subsidiary Just Brands LLC. The No Cap acquisition is expected to add some 75 SKUs to Flora’s product portfolio plus the “No Cap” and “Moonblunt” trademarks, according to a Sept. 7 company news release. “This transaction will allow Flora to immediately benefit from a profitable, cash flow positive and growing business,” Flora Growth Chairman and CEO Luis Merchan stated (https://ibn.fm/MAdTI). “We look forward to increasing our product offering through this transaction while broadening our sales team in the process.” Flora is headquartered in Canada where cannabis legalization has been pioneered, but the heart of the company’s operation is in northern Colombia, where its Cosechemos cultivation, extraction, and isolation facility, draws on an experienced workforce in the country’s fertile greenbelt to produce its brands. Colombia is itself undergoing a cannabis transformation as it enacts progressive drug policy changes, establishing a regulatory framework to govern cannabis cultivation and exports. In August, Flora announced a distribution agreement with the Misak indigenous tribe’s pharmaceutical arm, which became the first native community business to receive a license from the national Ministry of Justice for legal cannabis production for medicinal and scientific use two years ago (https://ibn.fm/eC25I). The deal allows Flora to take advantage of the tribe’s “unique regulatory positioning” to rapidly advance the fulfillment of cannabis exports. Merchan anticipates that the acquisition of No Cap’s brands will ultimately position Flora as the leader in the alternative cannabinoid market segment and that No Cap’s infusion technology will boost Flora Labs’ manufacturing capabilities. “We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward. With all three of our core pillars generating revenue in the second half of 2022 … we believe we have a path to profitability that few global cannabis companies can achieve in this difficult environment,” Merchan stated in August (https://ibn.fm/pU1hs). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• SGMD inks MSA with California cannabis micro license holder
• Agreement “lays a foundation for a significantly expanded manufacturing and distribution infrastructure,” says CEO
• Key partnerships are essential pieces of Sugarmade’s focus on California cannabis space

With the recent signing of a management services agreement (“MSA”) (https://ibn.fm/2KYof), Sugarmade (OTC: SGMD) is making key progress toward the goal of strengthening its position in the California cannabis space. SGMD signed the MSA through its subsidiary, SugarRush, which entered into the agreement with Canndis Inc., a California cannabis micro license holder. Canndis holds a license that covers delivery, manufacturing, distribution and cultivation rights, and the agreement will enable Sugarmade to expand its manufacturing and distribution footprint. “This deal will provide us with a new income stream as we apply our expertise and experience to mobilize Canndis’ assets and market positioning,” said Sugarmade CEO Jimmy Chan. “But it also has substantial strategic value because it lays a foundation for a significantly expanded manufacturing and distribution infrastructure under our control when we harvest our first crop.” Sugarmade is anticipating harvesting that crop in the coming weeks, an accomplishment made possible through the company’s acquisition of a minority stake in RMI Ventures (d/b/a Jerusalem Grade Farm) (https://ibn.fm/33N2u); the property is licensed for 43,560 square feet of outdoor canopy area and is currently growing at full capacity this season. Sugarmade and RMI Ventures signed an LOI earlier this year. These strategic agreements are essential pieces of Sugarmade’s focus on growing its presence in the cannabis space. The MSA calls for Sugarmade to assume management responsibilities and operational control over manufacturing and distribution of cultivated cannabis produced Jerusalem Grade Farm. The agreement also expands Sugarmade’s manufacturing and distribution footprint and will provide for the establishment of a new strategically located manufacturing and distribution hub near Palm Springs, California, as Sugarmade brings that harvest to market. Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue, J Grade Farm, Lemon Glow and Budcars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD